Incidence, Clinical Features, Management, and Prevention of Herpes Zoster in Patients Receiving Antitumor Necrosis Factor Therapy: A Clinical Review. Issue 3 (May 2020)

• Record Type: Journal Article
• Authors: Kim, Byung-Soo; Maverakis, Emanual; Alexanian, Clarie; Wang, Jenny Z.; Raychaudhuri, Siba P.
• Is Part Of: Journal of cutaneous medicine and surgery. Volume 24:Issue 3(2020)
• Page Start: 278
• Page End: 284
• Publication Date: 2020-05
• Subjects: herpes zoster -- anti-TNF therapy -- TNF inhibitors -- TNF antagonists -- vaccination -- varicella zoster virus; Dermatology -- Periodicals; Skin -- Diseases -- Treatment -- Periodicals; Skin -- Surgery -- Periodicals; Dermatology -- Canada -- Periodicals; Skin -- Diseases -- Treatment -- Canada -- Periodicals; Skin -- Surgery -- Canada -- Periodicals; 616.5005
• DOI: 10.1177/1203475420914622
• Languages: English
• ISSNs: 1203-4754

Abstract

Tumor necrosis factor (TNF) inhibitors have been used as an excellent therapeutic option in a variety of chronic inflammatory conditions. However, a recognized significant adverse effect of TNF inhibitor therapy is the increased risk of infections. The influence of TNF inhibitors on the course of coexisting or newly developed viral infections has not been extensively investigated. Therefore, we reviewed the recent publications to highlight the incidence, clinical features, management, and prevention of herpes zoster in patients who are receiving TNF inhibitors.